Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Molecular Partners AGNASDAQ: MOLN

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of CHF 14.47M (cash outflow) fell 17.5% year over year, behind the -8.4% change in trailing-twelve-month free cash flow. Sequentially, it rose 6.2% from the prior quarter.

Context

  • Free cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -17.5% toward the trailing-twelve-month pace of -8.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 14.47M+6.2% QoQ
Last fiscal yearDec 2025
-CHF 51.97M-13.3% YoY
LTMMar 2026
-CHF 54.13M-8.4% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.5%——
1 year-13.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

CHF · from the cash flow

Latest · FY2025
(51.97M) CHF
Year-over-year change
+13.3%

Free Cash Flow vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.4% is the 5th highest of 9, against a peer median of -9.8%.
MOLN Competitors
Free Cash Flow for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$173.2M USD-24.7%+96.0%940.4%
NKTXNkarta, Inc.LTM Mar 2026$88.39M USD-16.3%-4.8%—
PEPGPepGen Inc.LTM Mar 2026$77.27M USD-7.3%+9.1%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$73.65M USD+46.6%+19.8%—
MOLNMolecular Partners AGLTM Mar 2026CHF 54.13M CHF-8.4%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$51.23M USD+51.1%-2.2%2871.8%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$38.49M USD+9.5%+17.4%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$37.46M USD-12.4%+3.0%7135.4%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$17.11M USD-50.5%-26.9%540.0%
Peer median (excluding MOLN) —-9.8%+6.1%1906.1%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
Deferred Income Tax2K002K2K
Stock-Based Compensation4.09M5.09M5.21M4.11M4.42M
Change in Working Capital(34.67M)(6.01M)(6.01M)(3.8M)1.16M
Accounts Receivables(23.37M)25.26M(933K)(347K)463.2K
Inventory21.72M(19.93M)000
Accounts Payables1.66M(5.34M)(812K)524K62.08K
Other Working Capital(34.67M)(6.01M)(4.27M)(3.97M)630.33K
Other Non-Cash Items848K(753K)1.36M(7.88M)2.67M
Operating Cash Flow(90.95M)118.57M(59.01M)(59.25M)(51.26M)
Capital Expenditures(1.31M)(1.42M)(575K)(723K)(714K)
Acquisitions (Net)374K0000
Purchases of Investments(88.88M)(299.42M)(277.83M)(240.05M)(66.28M)
Sales of Investments67.88M199.22M319.44M277.02M137.81M
Other Investing Activities(304K)494K3.83M4.22M1.73M
Investing Cash Flow(22.24M)(101.12M)44.64M40.49M72.55M
Debt Repayment(1.18M)(1.19M)(1.2M)(1.21M)(1.21M)
Common Stock Issued51.49M250K31K17.34M63K
Common Stock Repurchased0(631K)000
Dividends Paid00000
Other Financing Activities267K250K31K(1.7M)0
Financing Cash Flow50.58M(1.57M)(1.17M)14.43M(1.15M)
Effect of Forex Changes701K258K(5.1M)894K(1.36M)
Net Change in Cash(61.91M)16.13M(20.64M)(3.44M)18.78M
Free Cash Flow(92.26M)117.15M(59.81M)(59.97M)(51.97M)

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.